Skip to main content
HR 1964 107th Congress House Health Access to health care Advertising Alternative medicine Civil Rights and Liberties, Minority Issues Commerce Conflict of interests Defective products Drug adulteration Drug approvals Drug industry Drug interactions Drug therapy Drugs Electronic government information Government Operations and Politics Government paperwork Government publicity Governmental investigations Informed consent (Medical law)

Access to Medical Treatment Act of 2001

Introduced: May 23, 2001 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 8, 2001
Referred to the Subcommittee on Health.
May 23, 2001
Referred to the House Committee on Energy and Commerce.
May 23, 2001
Introduced in House
 Plain-English summary Congressional Research Service
Access to Medical Treatment Act of 2001 - Defines: (1) "danger" as an adverse reaction to an unapproved drug or medical device that used as directed causes serious harm which would not otherwise have occurred, or harm more serious than side effects for drugs or medical devices approved by the Federal Food and Drug Administration (FDA) for the same disease or condition; and (2) other terms as used in this Act, including "health care practitioner" and "unapproved drug or medical device."

Allows a patient to receive, and the practitioner to provide or administer, any unapproved drug or medical device the patient or their legal representative desires, provided certain conditions are met. Sets forth circumstances under which a health care practitioner may recommend, provide, or administer an unapproved drug or medical device.

Requires a practitioner who discovers that an unapproved drug or medical device creates a danger to a patient immediately to cease use and recommendation of such drug or device and provide specified information to its manufacturer and the Director of the Centers for Disease Control and Prevention. Requires the manufacturer that receives such information to: (1) immediately cease sale and distribution of the drug or device; and (2) comply with specified notification and reporting requirements. Sets forth certain investigative and reporting duties that the Director, the Secretary of Health and Human Services, and a practitioner must perform with respect to the dangerousness or effectiveness of unapproved drugs or medical devices.

Sets forth a penalty for violations of this Act.

What's happening now June 8, 2001

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2
 Cosponsors 2
All 2 Republican 1 Independent 1